EHA Library - The official digital education library of European Hematology Association (EHA)

FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ΑLPHA AND C-MYC IN CLL CELLS
Author(s): ,
Viola Meyer-Pannwitt
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany;Department of Molecular Genetics (B061), Cooperation Unit 'Mechanisms of Leukemogenesis', DKFZ,Heidelberg,Germany
,
Sven Estenfelder
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany
,
Eugen Tausch
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany
,
Sabrina J. Kugler
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany;Department of Molecular Genetics (B061), Cooperation Unit 'Mechanisms of Leukemogenesis', DKFZ,Heidelberg,Germany
,
Michaela Reichenzeller
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany;Department of Molecular Genetics (B061), Cooperation Unit 'Mechanisms of Leukemogenesis', DKFZ,Heidelberg,Germany
,
Stephan Stilgenbauer
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany
Daniel Mertens
Affiliations:
Internal Medicine III, Ulm University,Ulm,Germany;Department of Molecular Genetics (B061), Cooperation Unit 'Mechanisms of Leukemogenesis', DKFZ,Heidelberg,Germany
(Abstract release date: 05/18/17) EHA Library. Meyer-Pannwitt V. 06/23/17; 181403; S116
Viola Meyer-Pannwitt
Viola Meyer-Pannwitt
Contributions
Abstract

Abstract: S116

Type: Oral Presentation

Presentation during EHA22: On Friday, June 23, 2017 from 11:45 - 12:00

Location: Hall D

Background
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with recurrent mutations that are of pathogenic and prognostic relevance. Mutations in FBXW7 are among the most common mutations in CLL, yet their functional consequences are unknown. FBXW7 is an E3 ubiquitin ligase that ubiquitylates oncoproteins like NOTCH1, HIF1-α and c-MYC and thereby targets them for proteasomal degradation.

Aims

2.5-4% of CLL patients harbor FBXW7 mutations. Approximately 60% of FBXW7 mutations alter arginine residues that are involved in substrate targeting. In T-cell acute lymphoblastic leukemia these arginine mutations are associated with chemotherapy resistance. In CLL however, the role of dysfunctional FBXW7 is unclear. We therefore aimed to delineate the prevalence of FBXW7 mutations in CLL patient cohorts and characterize its functional role.

Methods
FBXW7 mutations were analyzed via amplicon-based targeted next generation sequencing in primary CD19-sorted samples of previously untreated CLL patients (n=905) as well as in CLL (n=8), MCL (n=5), T-ALL (n=2), Burkitt lymphoma (n=1) and LCL cell lines (n=3). In silico modeling with PolyPhen-2 predicted a potential impact of the mutations on the structure and function of FBXW7. For functional analysis, FBXW7 mutations were induced using CRISPR/Cas9 in the CLL cell line HG3, which does not harbor a NOTCH1 mutation. Both in this CRISPR/Cas9 mutated cell line and in primary CLL cells with FBXW7 mutations, the protein levels of FBXW7 substrates were examined. In addition, we quantified NOTCH1 and HIF1-α activity with Luciferase reporter assay in FBXW7 mutated HG3 cell lines.

Results
Heterozygous mutations in FBXW7 were found in 41/905 (4.5%) of CLL patients. The most common mutations of FBXW7 were missense mutations (32/41) that target the substrate binding domain of the FBXW7 protein as well as non-sense mutations (4/41). Interestingly, 5 patients harbored two concurrent FBXW7 mutations. By the use of the PolyPhen-2 software, all except one missense mutation in FBXW7 were predicted to be most likely damaging. No mutations in FBXW7 were found in the CLL, MCL and LCL cell lines analyzed. To determine the functional consequence of FBXW7 mutations in CLL, we induced either a heterozygous or a homozygous truncation of FBXW7 in the CLL cell line HG3, resulting in the loss of the substrate binding site of the WD40 domain. The homozygous truncation of FBXW7 resulted in an increase of NOTCH1, HIF1-α and c-MYC protein levels, whereas no difference of Cyclin E protein amount was detectable. In addition, an elevation of NOTCH1 activity was found in both the heterozygously and homozygously truncated mutant cell lines in comparison to the wildtype HG3 cell line. To confirm this finding, protein levels of 5 CLL patients with FBXW7 mutations were analyzed with a similar outcome.

Conclusion

Mutations in FBXW7 are frequently found in CLL, especially missense and nonsense mutations affecting the WD40 domain. We hypothesize that this has functional consequences on FBXW7 substrate binding and hence leads to accumulation of oncogenes. In line, the induced truncation of the WD40 domain of FBXW7 in the HG3 cell line resulted in the accumulation of protein substrates and corresponding increase of their activity implicated in the pathogenesis of CLL. Taken together our data show that FBXW7 can target proteins for degradation that are commonly dysregulated in CLL and that drive disease progression.

Session topic: 5. Chronic lymphocytic leukemia and related disorders - Biology

Keyword(s): Chronic Lymphocytic Leukemia, Ubiquitination, Notch, MYC

Abstract: S116

Type: Oral Presentation

Presentation during EHA22: On Friday, June 23, 2017 from 11:45 - 12:00

Location: Hall D

Background
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with recurrent mutations that are of pathogenic and prognostic relevance. Mutations in FBXW7 are among the most common mutations in CLL, yet their functional consequences are unknown. FBXW7 is an E3 ubiquitin ligase that ubiquitylates oncoproteins like NOTCH1, HIF1-α and c-MYC and thereby targets them for proteasomal degradation.

Aims

2.5-4% of CLL patients harbor FBXW7 mutations. Approximately 60% of FBXW7 mutations alter arginine residues that are involved in substrate targeting. In T-cell acute lymphoblastic leukemia these arginine mutations are associated with chemotherapy resistance. In CLL however, the role of dysfunctional FBXW7 is unclear. We therefore aimed to delineate the prevalence of FBXW7 mutations in CLL patient cohorts and characterize its functional role.

Methods
FBXW7 mutations were analyzed via amplicon-based targeted next generation sequencing in primary CD19-sorted samples of previously untreated CLL patients (n=905) as well as in CLL (n=8), MCL (n=5), T-ALL (n=2), Burkitt lymphoma (n=1) and LCL cell lines (n=3). In silico modeling with PolyPhen-2 predicted a potential impact of the mutations on the structure and function of FBXW7. For functional analysis, FBXW7 mutations were induced using CRISPR/Cas9 in the CLL cell line HG3, which does not harbor a NOTCH1 mutation. Both in this CRISPR/Cas9 mutated cell line and in primary CLL cells with FBXW7 mutations, the protein levels of FBXW7 substrates were examined. In addition, we quantified NOTCH1 and HIF1-α activity with Luciferase reporter assay in FBXW7 mutated HG3 cell lines.

Results
Heterozygous mutations in FBXW7 were found in 41/905 (4.5%) of CLL patients. The most common mutations of FBXW7 were missense mutations (32/41) that target the substrate binding domain of the FBXW7 protein as well as non-sense mutations (4/41). Interestingly, 5 patients harbored two concurrent FBXW7 mutations. By the use of the PolyPhen-2 software, all except one missense mutation in FBXW7 were predicted to be most likely damaging. No mutations in FBXW7 were found in the CLL, MCL and LCL cell lines analyzed. To determine the functional consequence of FBXW7 mutations in CLL, we induced either a heterozygous or a homozygous truncation of FBXW7 in the CLL cell line HG3, resulting in the loss of the substrate binding site of the WD40 domain. The homozygous truncation of FBXW7 resulted in an increase of NOTCH1, HIF1-α and c-MYC protein levels, whereas no difference of Cyclin E protein amount was detectable. In addition, an elevation of NOTCH1 activity was found in both the heterozygously and homozygously truncated mutant cell lines in comparison to the wildtype HG3 cell line. To confirm this finding, protein levels of 5 CLL patients with FBXW7 mutations were analyzed with a similar outcome.

Conclusion

Mutations in FBXW7 are frequently found in CLL, especially missense and nonsense mutations affecting the WD40 domain. We hypothesize that this has functional consequences on FBXW7 substrate binding and hence leads to accumulation of oncogenes. In line, the induced truncation of the WD40 domain of FBXW7 in the HG3 cell line resulted in the accumulation of protein substrates and corresponding increase of their activity implicated in the pathogenesis of CLL. Taken together our data show that FBXW7 can target proteins for degradation that are commonly dysregulated in CLL and that drive disease progression.

Session topic: 5. Chronic lymphocytic leukemia and related disorders - Biology

Keyword(s): Chronic Lymphocytic Leukemia, Ubiquitination, Notch, MYC

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies